adavosertib
Small moleculeexperimental
Adavosertib is an experimental anti-cancer drug candidate. It is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. It is being developed by AstraZeneca. It is being investigated as a treatment for pancreatic cancer with a phase 1 trial, and ovarian cancer, in combination with another anti-cancer drug, gemcitabine, as a phase 2 trial. — Wikipedia
Clinical trial activity
14 trials · 17 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Mar 13, 2017 (NCT04439227)
Timeline
Indications
Studied for
- Brain Neoplasms · Phase 1
- Breast Neoplasms · Phase 2
- Carcinoma, Endometrioid · Phase 1
- Endometrial Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 2
- Hamartoma · Phase 2
- Lymphoma · Phase 2
- Multiple Myeloma · Phase 2
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 2
- Stomach Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
- Uterine Neoplasms · Phase 2
- Vaginal Neoplasms · Phase 1
Mechanism of action
- Serine/threonine-protein kinase WEE1INHIBITOR
WEE1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAdavosertib ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05212025 | Phase 2 | Jun 30, 2022 | AstraZeneca, Harvard University, Lustgarten Foundation, Stand Up To Cancer |
| NCT05008913 | Phase 1 | Oct 1, 2021 | AstraZeneca, Parexel |
| NCT04949425 | Phase 1 | Sep 13, 2021 | AstraZeneca, Parexel |
| NCT04959266 | Phase 1 | Jun 28, 2021 | AstraZeneca, Parexel |
| NCT04590248 | Phase 2 | Nov 30, 2020 | AstraZeneca, Harvard University, Parexel |
| NCT04460937 | Phase 1 | Nov 21, 2020 | National Cancer Institute (NCI), Ohio State University |
| NCT04462952 | Phase 1 | Jun 24, 2020 | AstraZeneca |
| NCT04197713 | Phase 1 | Mar 27, 2020 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT03579316 | Phase 2 | Nov 30, 2018 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT03253679 | Phase 2 | Oct 6, 2018 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT03330847 | Phase 2 | Feb 21, 2018 | AstraZeneca, Guy's and St Thomas Hospital |
| NCT03385655 | Phase 2 | Dec 12, 2017 | British Columbia Cancer Agency, Canadian Cancer Clinical Trials Network, Canadian Cancer Trials Group, Hamilton Health Sciences Corporation, University of Alberta, University of Ottawa |
| NCT03345784 | Phase 1 | Oct 23, 2017 | National Cancer Institute (NCI), University of Toronto |
| NCT04439227 | Phase 2 | Mar 13, 2017 | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 7 | 6 | 2 | 2018 |
| National Cancer Institute (NCI) | Government | 6 | 5 | 2 | 2017 |
| Parexel | For profit | 4 | 0 | 2 | 2020 |
| University of Texas at Houston | Academic/Hospital | 3 | 1 | 2 | 2018 |
| Harvard University | Academic/Hospital | 2 | 1 | 1 | 2020 |
| British Columbia Cancer Agency | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Canadian Cancer Clinical Trials Network | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Canadian Cancer Trials Group | Academic/Hospital | 1 | 1 | 1 | 2017 |
| ECOG-ACRIN Cancer Research Group | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Guy's and St Thomas Hospital | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Hamilton Health Sciences Corporation | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Lustgarten Foundation | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Stand Up To Cancer | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Alberta | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Ottawa | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2017 |
17 organizations
Page 1 / 1